Amlodipine: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 52: | Line 52: | ||
==See Also== | ==See Also== | ||
*[[Calcium channel blocker toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Revision as of 16:56, 19 September 2019
General
- Type: Antihypertensive (dihydropyridine-CCB)
- Dosage Forms: tablet
- Dosage Strengths: 2.5mg, 5mg, 10mg
- Routes of Administration: PO
- Common Trade Names: Norvasc
Adult Dosing
- hypertension
- 5-10mg PO qDaily
- Start: 5mg PO qDaily for intial antihypertesnive, do 2.5 if elderly or 2nd line drug
Pediatric Dosing
- hypertension
- 2.5-5mg PO qDaily
Special Populations
- Pregnancy Rating: C
- Lactation: Safety Unknown
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: Start at 2.5mg qDaily
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Severe CAD, AS, CHF
- Re-dose/Caution: Elderly/Hepatic Impairment
Adverse Reactions
Serious
- Angina, MI
- Hypotension
- Hepatitis
- Erythema multiforme
Common
- Peripheral edema
- Fatigue
- Palpitations
- Dizziness
- Nausea
- Flushing
- Eczematous eruptions
Pharmacology
- Half-life: 30-50h
- Metabolism: liver extensively; CYP450: 3A4
- Excretion: urine 59-62% (5-10% unchanged), bile/feces 20-25%
- Mechanism of Action: CCB-dihydropyridine